Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis-Reference-Cited by-同舟云学术

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

Published:2014-11-20 Issue:7 Volume:56 Page:2067-2074
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Jung Chul Won,Shih Lee-Yung,Xiao Zhijian,Jie Jin,Hou Hsin-An,Du Xin,Wang Ming-Chung,Park Seonyang,Eom Ki-Seong,Oritani Kenji,Okamoto Shinichiro,Tauchi Tetsuzo,Kim Jin Seok,Zhou Daobin,Saito Shigeki,Li Junmin,Handa Hiroshi,Jianyong Li,Ohishi Kohshi,Hou Ming,Depei Wu,Takenaka Katsuto,Liu Ting,Hu Yu,Amagasaki Taro,Ito Kazuo,Gopalakrishna Prashanth,Akashi Koichi

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.969260

Reference19 articles.

1. Therapeutic approaches in myelofibrosis

2. MPN-associated myelofibrosis (MPN-MF)

3. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)

4. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

5. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: A case of effective treatment of primary myelofibrosis with nodular panniculitis using ruxolitinib combined with corticosteroids;Frontiers in Oncology;2024-08-19

2. Clinical outcomes of chemotherapy in cancer patients with different ethnicities;Cancer Reports;2023-05-07

3. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review;Clinical Pharmacokinetics;2023-03-31

4. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases;European Journal of Medicinal Chemistry;2022-09

5. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study;Arthritis Research & Therapy;2022-07-28